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Abstract
The kinase MEKK2 (MAP3K2) has recently been implicated in tumor growth and metastasis.
Thus, selective inhibition of MEKK2 may be a novel strategy for cancer therapy. In order to
identify inhibitors of MEKK2 kinase activity, we have developed a novel activity assay for
MEKK2 based on the discovery that recombinant purified MEKK2 has intrinsic ATPase activity.
This MEKK2 ATPase assay was validated for enzyme identity and enzymatic purity by multiple
methods including mass spectrometry analysis, testing different sources of MEKK2 and
comparing ATPase assay IC50 data for multiple inhibitors to literature values and to IC50 data
generated using MEKK2 binding and transphosphorylation assays. Taken together, these data
indicated that genuine MEKK2 activity was being measured in this assay and no other ATPases
contributed to the signal. A miniaturized version of the assay was validated for high throughput
screening and compound libraries were screened. The screening hits generated comparable
potencies in the MEKK2 intrinsic ATPase, binding and transphosphorylation assays. We
identified a novel MEKK2 inhibitor and confirmed that crizotinib and bosutinib are potent in vitro
inhibitors of MEKK2 activity with IC50 values of <100 nM. Thus, this assay has utility for the
discovery of small molecule inhibitors of MEKK2 activity.
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INTRODUCTION
Mitogen-activated protein kinases (MAPK) are critical cell signaling components that
transduce extra-cellular stimuli to the nucleus ultimately leading to changes in gene
expression1–2. ERK5 is a MAPK that is activated by a number of growth factors, oxidative
stress, and hyperosmolarity3. Disruption of the ERK5 gene in mice resulted in embryonic
lethality due to defects in cardiac development and angiogenesis4. ERK5 protects many cell
types from stress-induced apoptosis3, 5–6. MEK5 is the only MAP2K for the ERK5
pathway7. MEK5 gene knock out in mice was lethal and resulted in abnormal cardiac
development, similar in phenotype to the ERK5 knockout mouse7. The only defined
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MAP3Ks for the ERK5 pathway are MEKK2 (MAP3K2) and MEKK3 (MAP3K3)8–9.
These kinases phosphorylate MEK5 and activate its activity. Disruption of the MEKK2 gene
in mice resulted in normal development and fertility10–11. In contrast, the disruption of
MEKK3 resulted in embryonic lethality due to cardiac development defects that mimicked
the ERK5 knockout phenotype12. Thus, the different phenotypes of these transgenic animals
demonstrate that these two MAP3Ks integrate different stimuli. MEKK2 activates both the
ERK5 and JNK pathways10, 13. MEKK2 has been observed to autophosphorylate in
response to stimuli and this autophosphorylation is required for activation of MEKK214.
The role of the ERK5 pathway in cancer has only relatively recently been explored.
Expression of ERK5 in a panel of 84 human early stage breast cancer tissue samples was
examined and overexpression of ERK5 was found in 20% of the samples15. Overexpression
of ERK5 correlated with a decrease in disease-free survival time. In a similar study done
with prostate cancer, ERK5 expression was significantly increased in high-grade prostate
cancer compared to benign prostatic hyperplasia16–17. Analysis of ERK5 expression in
samples taken before and after hormone relapse showed a correlation with ERK5 activation
and hormone-insensitive disease17. ERK5 overexpression in PC3 cells resulted in more
efficient tumor formation in mice. In another study, a dominant negative form of ERK5
restricted the proliferation of myeloma cells and sensitized the cells to apoptosis-inducing
drugs18. In a recent study, miR-143 was shown to be a tumor suppressor in prostate cancer
using a mouse model19. One of the mechanisms of miR-143 appears to be suppression of
ERK5 protein expression. Activation of the ERK5 pathway, but not the ERK1 pathway, was
correlated with lymph node metastasis in oral squamous cell carcinoma20. A potent and
selective ERK5 inhibitor has been reported that inhibited tumor growth in an in vivo mouse
cancer model21. MEK5 has also been implicated in tumor development. MEK5 expression
was determined in 127 cases of prostate cancer and 20 cases of benign prostatic
hypertrophy22. The data indicated that elevated expression of MEK5 correlated with bone
metastasis and poor prognosis. In one study linking MEKK2 to cancer, 11 prostate cancer
tissue samples were compared to uninvolved prostate tissue using imaging mass
spectrometry (MS)16. One peptide was found to discriminate cancer from uninvolved tissue.
This peptide was a fragment of MEKK2. In confirmation of the MS data, MEKK2 was
expressed at 4.4-fold higher level in prostate cancer tissue versus benign tissue using
western blotting. Even higher levels of MEKK2 expression were observed in LNCaP,
Du145 and PC3 prostate cell lines.
We have recently examined the role of MEKK2 in tumor growth and metastasis using an in
vivo mouse xenograft model for breast cancer23. We found that shRNA-mediated
knockdown of MEKK2 inhibited activation of ERK5 in response to EGF in the breast
cancer cell line MDA-MB-231. Knockdown of MEKK2 expression strongly inhibited both
tumor growth and metastasis. Increased apoptosis was observed with the loss of MEKK2
expression in xenografts versus size-matched control tumors, even though growth of
MEKK2 knockdown cells in culture was unaffected. MEKK2 shRNA knockdown in the
BT474 cell line also resulted in inhibited tumor growth in xenografts. Thus, MEKK2 is
critical for EGFR- and Her2/Neu tyrosine kinase-dependent ERK5 activation, tumor growth
of both MDA-MB-231 and BT474 cells, and metastasis of MDA-MB-231 cells. Because
MEKK2 is required for EGFR activation of ERK5, we assessed whether knockdown of
ERK5 in MDA-MB-231 cells would show similar tumor growth and metastasis phenotypes
as with MEKK2 knockdown. ERK5 knockdown resulted in a decrease in metastasis without
a significant effect on tumor growth. Thus, MEKK2 regulation of ERK5 is only one arm of
MEKK2 signaling controlling tumor growth and metastasis. These results further support
MEKK2 as a novel target for small molecule inhibitor development.
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Kinase intrinsic ATPase activity is the hydrolysis of ATP to ADP and phosphate in the
absence of a phosphate-accepting substrate. Intrinsic ATPase activity has been observed for
a number of kinases using in vitro biochemical assays and purified kinase. This ATPase
activity has been described for several MAPKs, including p38α, p38γ, ERK2, JNK3 and
MEK124–25. A format comparison study compared screening results using an antibody-
based disassociation-enhanced lanthanide fluoroimmunoassay (DELFIA), an ATP-
consumption intrinsic ATPase assay, and a fluorescence polarization binding assay for
ITK26. The authors concluded that the intrinsic ATPase assay identified the most
comprehensive set of inhibitors from screening. In another study using PI3Kα, IC50 data for
a panel of inhibitors generated using an intrinsic ATPase assay was similar to data generated
by a lipid phosphorylation assay27.
We have discovered that MEKK2 has intrinsic ATPase activity and developed a high
throughput MEKK2 activity assay based on this property. Multiple methods were employed
to demonstrate that genuine MEKK2 activity was being measured and no other ATPase
activities contributed to assay signal. In addition, a miniaturized version of the assay was
validated for HTS and compound libraries were screened. Using this assay, a novel MEKK2
inhibitor was identified and crizotinib and bosutinib were confirmed to inhibit MEKK2
activity with IC50 values of <100 nM.
MATERIALS AND METHODS
Materials
All common reagents such as HEPES, Triton X-100, MgCl2, ethylene glycol tetraacetic acid
(EGTA), sodium orthovanadate, ß-glycerophosphate, dithiothreitol (DTT) and dimethyl
sulfoxide (DMSO) were reagent-grade quality and obtained from Thermo Fisher Scientific
(Waltham, MA) or Sigma-Aldrich (St. Louis, MO). The ADP-Glo™ kinase assay kit (cat#
V9102), containing ADP-Glo™, detection reagent and ultra pure ATP was obtained from
Promega (Madison, WI). Solid white 96-well half-area plates (cat# 3693) for the manual
activity assay and 384-well low volume white plates (cat# 3673) for high throughput activity
assay and binding assay were from Corning Incorporated (Corning, NY). Falcon
polypropylene plates (cat# 1190) used for serial dilutions of compounds for manual activity
and binding assays were obtained from Becton Dickinson (Franklin Lake, NJ). Kinase
inhibitors were obtained from Fisher Chemical (Waltham, MA), LC Laboratories (Woburn,
MA), Selleck Chemicals (Houston, TX), AK Scientific (Union City, CA), Biovision
(Milpitas, CA), Toronto Research Chemicals (Toronto Canada) and Symansis (Shanghai,
China). The validation set of compounds for test screening was obtained from Prestwick
Chemical (Washington DC). The kinase-focused library of compounds was obtained from
The Center for Integrative Chemical Biology and Drug Discovery at the University of North
Carolina at Chapel Hill (Chapel Hill, NC). Recombinant purified MEKK2 enzyme was
obtained from SignalChem (Richmond, BC, Canada) (vendor 1), Invitrogen (Grand Island,
NY) (vendor 2) and Carna Bioscience (Kobe, Japan) (vendor 3). We used the MEKK2
enzyme from SignalChem (vendor 1) to generate the data shown in this report unless
otherwise indicated. LanthaScreen Eu-anti-GST antibody (cat# PV5594) and Kinase Tracer
236 (cat# PV5592) used in the binding assays were obtained from Invitrogen. Protease
digestion and matrix-assisted laser desorption/ionization-time of flight/time of flight
(MALDI-TOF/TOF) analysis of the MEKK2 solution was performed by the Proteomics
Core Facility, UNC-Chapel Hill.
MEKK2 Intrinsic ATPase Activity Assay
All compound stock solutions were made in 100% DMSO. Serial dilutions of compounds
for IC50 determinations were initially performed in 100% DMSO in 96-well polypropylene
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plates, followed by appropriate dilutions in assay buffer (50 mM HEPES, pH 7.4, 10 mM
MgCl2, 0.5 mM EGTA, 0.5 mM sodium orthovanadate, 0.5 mM ß-glycerophosphate, 2.5
mM DTT and 0.01% Triton X-100), producing a constant 2.5% DMSO in all wells.
Subsequently, 10 μl of the diluted compound (or just 2.5% DMSO in assay buffer for
controls) were added to the wells of a 96-well plate followed by 10 μl of MEKK2 enzyme
diluted in assay buffer. After a 10 minute incubation, the reactions were initiated by addition
of 5 μl of ATP (150 μM ultrapure ATP from Promega kit) diluted in assay buffer and the
assay plates were centrifuged at 1000 RPM for 1 minute in a Beckman Coulter Allegra
X-12R centrifuge. Final concentrations in the assembled standard assay were as follows: 1x
assay buffer, 1% DMSO, 30 μM ATP and 10 nM MEKK2 enzyme. The enzyme reactions
were allowed to proceed protected from light for 75 minutes at 23ºC and terminated by the
addition of 25 μl of solution 1 (ADP-Glo™ Reagent, Promega). At this point assay plates
were centrifuged again as described above and incubated at 23°C for an hour. A 50 μL
volume of solution 2 (Detection Reagent) of the Promega kit was added to each well and the
plates incubated for an hour at 23ºC, protected from light. The plates were read using an
endpoint luminescence protocol (measurement interval time: 1.0 s, optic module: LUM plus,
gain: 3600, focal height: 13.7 mm, positional delay: 0.1 s) in a BMG PHERAstar (BMG
Labtech, Cary, NC) plate reader. Luminescence data, expressed in relative luminescence
units (RLU), were normalized to DMSO (100% activity) and “no enzyme” (0% activity)
controls as maximum and minimum responses, respectively.
For all MEKK2 assay formats, compound concentration response curves were generated
using data points that represent the average of three determinations per concentration, except
for the transphosphorylation assay where duplicate determinations were performed. All IC50
values provided in this report are averages of at least three independent determinations. The
IC50 values and Hill slopes were calculated from concentration response data using
GraphPad Prism software (GraphPad Software Inc., La Jolla, CA) employing either a four-
parameter or a three-parameter (fixed bottom) curve fit.
High Throughput MEKK2 Activity Assay
The activity assay described above was readily adapted to an automated 384-well assay
version where handling of compound dilutions, delivery of reagents and mixing was
performed on a Biomek® NX (Beckman Coulter Inc., Fullerton, CA) and a Nanoscreen
NSX 1536 (Charleston, SC). The automated assay was carried out exactly as the manual
assay including incubation times and centrifugation with the following modifications. 2.5
μL of enzyme solution was added to 384-well white solid low volume assay plates. 50nL
compounds in 100% DMSO (or 100% DMSO as controls) were added to each well using a
V&P Scientific pin tool (San Diego, CA). After 10 minutes 2.5 μL of ultrapure ATP was
added to each well, bringing the final assay volume to 5 μL. The reaction was terminated by
addition of 5 μL of solution 1 (ADP-GLO) and following 60 minutes incubation, 10 μL of
solution 2 (Detection Reagent) was added. The plates were sealed with Mylar® Plate Seals
(Thermo, Milford, MA) during incubations. The kinase inhibitor library was screened at 5
μM concentration and compounds with ≥50% inhibition were considered hits. Z’-factor
calculations were performed as published28.
MEKK2 TR-FRET Binding Assay
Compound dilution methods and assay buffer was the same for the MEKK2 time-resolved
fluorescence resonance energy transfer (TR-FRET) binding assay as in the ATPase assay.
The assay was performed according to the antibody and tracer manufacturer’s
recommendations (Invitrogen). Briefly, 5 μl of diluted compounds (or 3% DMSO for
controls) were added to wells of a solid white low volume 384-well plate followed by 5 μl
of a mixture of MEKK2 enzyme and LanthaScreen® Eu-anti-glutathione S-transferase
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(GST) antibody diluted in assay buffer. Immediately after addition of the enzyme-antibody
mixture, the reaction mixtures were completed by the addition of 5 μl of kinase tracer 236
diluted in assay buffer. The assay plates were then centrifuged at 1000 rpm for 1 minute as
before and incubated for 60 min at 23ºC. Final concentrations in the assembled assay were
as follows: 1% DMSO, 2 nM LanthaScreen® Eu-anti-GST antibody, 25 nM kinase tracer
and 5 nM MEKK2 enzyme. Time resolved fluorescence was measured using a BMG
PHERAstar with the following parameters: number of flashes per well: 300, optic module:
HTRF, excitation: 337 nm, emission A: 665 nm, emission B: 620 nm, integration start (μs):
100, integration time (μs): 200, focal length: 10.3 mm, ratio multiplier: 1000, positional
delay: 0.1. TR-FRET signal was calculated by determined the ratio of relative fluorescence
units (RFU) obtained at 665 nm and 620 nm (665 nm/620 nm) and subsequently
normalizing the value to DMSO (100% activity) and 30 μM dasatinib (0% activity) controls
as maximum and minimum responses, respectively.
MEKK2 Transphosphorylation Activity Assay
The MEKK2 transphosphorylation activity assay and IC50 determinations were performed
as described for the ATPase assay except the reactions were initiated by a mixture of ATP
and kinase-inactive mutant MKK6 (MAP2K6, Carna Biosciences). Final concentrations in
the enzyme reactions were 2 nM MEKK2, 200 nM MKK6 and 3 μM ATP. The reaction
time was 25 min and the reactions were stopped by the addition of 225 μl of stop buffer (25
mM HEPES, pH 7.4, 10 mM EDTA). These reactions were then transferred to PVDF
membranes using a slot blot apparatus (Hoefer PR 648) following the manufacturer’s
recommendations. The membrane was allowed to dry and then probed with an anti-
phosphoMKK6 antibody (Phospho-MKK3 (Ser189)/MKK6 (Ser207) (22A8) rabbit
monoclonal antibody, Cell Signaling, Danvers, MA) using a standard western blotting
protocol29.
RESULTS
Characterization of MEKK2 intrinsic ATPase activity
We sought to develop a high throughput activity assay for MEKK2 in order to identify small
molecule inhibitors of this kinase. Using a sensitive chemiluminescent ADP detection assay
(ADP-Glo kit, Promega), we observed ATPase activity using purified recombinant MEKK2
enzyme in the absence of any protein substrate. This ATPase activity increased in a linear
fashion directly proportional to the concentration of MEKK2 in the reaction up to 10 nM
(Fig. 1A). ATPase activity was readily detected even at 1 nM MEKK2. Reaction time course
studies with 10 nM MEKK2 demonstrated linear assay signal increase from 0 – 90 min (Fig.
1B). Thus, we chose final reaction conditions of 10 nM MEKK2 and a reaction time of 75
min. The Km for ATP was determined by performing reactions with variable concentrations
of ATP with and without MEKK2 (Fig. 1C). Reactions without MEKK2 were taken as
background and subtracted from the signal obtained with enzyme to obtain specific RLU.
The average Km value was 34 μM and thus we chose to use 30 μM ATP for the final assay.
We also used pure ADP to determine a standard curve (data not shown). Under final
standard assay conditions, we calculated that approximately 3 μM ADP was generated,
translating into a 10% substrate conversion (ATP to ADP). The activity observed in this
assay is unlikely to be MEKK2 autophosphorylation activity based on the ratio of the
amount of product formed to the MEKK2 enzyme concentration. Since there is only 10 nM
MEKK2 and 3,000 nM ADP generated during the course of the reaction, each molecule of
MEKK2 would have to be autophosphorylated 300 times – roughly twice the sum of all the
serine, threonine and tyrosine residues in the GST-MEKK2 construct. Since this assay
would be used to test compounds dissolved in DMSO, the DMSO tolerance of the assay was
assessed (Fig. 1D). Up to 8% DMSO was tolerated in the assay without significant effect.
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The final DMSO concentration in the reaction under final assay conditions was set at 1%
DMSO.
Validation of the identity and enzymatic purity of MEKK2 in the intrinsic ATPase activity
assay
We purchased purified recombinant human MEKK2 and confirmed its identity by mass
spectrometry analysis. The entire MEKK2 enzyme (vendor 1) solution was subjected to
enzymatic digestion followed by MALDI TOF/TOF MS analysis of the resulting peptides.
Peptides matching human MEKK2 were observed, but no other peptides were detected (data
not shown).
Non-selective assay formats, such as measuring ADP generation for kinase assays, require
an extra amount of enzymatic purity validation to prove that the target activity, and only that
activity, is being measured. We used several experimental approaches to validate that the
observed ATPase activity was due to MEKK2 and only MEKK2. In one approach, we
obtained purified recombinant human MEKK2 from three different vendors since if
contamination is the source of activity, then it is less likely (though possible) that the all
three sources would have the same contaminating ATPase at the same concentration or
activity level. We demonstrated that all three sources of MEKK2 had time dependent
ATPase activity with similar specific activities, since they were all tested at 10 nM MEKK2
(Fig. 2A). Furthermore, we used sunitinib as a control inhibitor to determine its potency
using all three sources of MEKK2 (Fig. 2B). The concentration response data produced
average IC50 values and standard deviations (SDs) of 337 ± 157, 184 ± 80, and 315 ± 199
nM for MEKK2 from vendors 1, 2 and 3, respectively. The sunitinib potencies were all
within two-fold of each other and therefore these data suggested that the same enzyme
activity was being measured in all three sources of MEKK2. When inhibiting a single
enzyme in any biochemical assay, a Hill slope of 1.0 is indicative of the measurement of a
single enzyme – versus multiple enzymes that could be present and detected in the assay.
Broad (<1) slopes may indicate that more than one enzyme is being measured in the assay.
Thus, we also analyzed the Hill slope data from these IC50 curves. The average Hill slope
values and SDs from these inhibitor curves were 1.06 ± 0.16, 1.01 ± 0.02 and 1.01 ± 0.05
for vendors 1, 2 and 3, respectively. The slopes for the different MEKK2 sources were very
close to 1.0 indicating that a single ATPase enzyme was being measured and inhibited in all
three sources of MEKK2. Sunitinib also demonstrated complete inhibition of activity at high
compound concentrations (Fig. 2B) which is also expected for measurement of a single
enzyme activity. It should also be noted that vendor 3 MEKK2 is different from the other
two in that the vendor 3 protein construct consists of only the catalytic domain of MEKK2.
These data from different sources of MEKK2 indicate that MEKK2 has intrinsic ATPase
activity in vitro. Vendor 1 MEKK2 was used for all experimental data and screening shown
and cited in this report except as indicated in Figure 2.
We further validated that the assay was measuring genuine MEKK2 activity and not a
contaminant ATPase or kinase, by using a panel of 4 kinase inhibitors for inhibitor-based
enzymatic purity studies. Inhibitor concentration response curves were generated for
sunitinib, dasatinib, VX-680 and staurosporine using the intrinsic ATPase activity assay
(Fig. 2C). Sunitinib, dasatinib and VX-680 generated IC50 values (nM) and SDs of 337 ±
157, 753 ± 268 and 3,603 ± 826, respectively (Table 1). These values are comparable
(within 3-fold and the same rank order) to data provided by Invitrogen using their MEKK2
TR-FRET binding assay (Lanthascreen) (Table 1). Staurosporine is a very potent inhibitor of
MEKK2 and behaved as a tight binding inhibitor in the ATPase assay. Therefore, the
MEKK2 concentration in the reaction was reduced to 1 nM to obtain valid IC50 and Hill
slope data for staurosporine. Titration of staurosporine resulted in an average IC50 and SD of
1.0 ± 0.6 nM (Table 1). This IC50 value also favorably compared to the reported Invitrogen
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TR-FRET binding assay IC50 of 4.2 nM for staurosporine. Using a different bead-based
competition binding assay for MEKK2, Kd values for these same compounds were
published as part of a large kinase profiling panel30. This published binding data gave the
same rank order as we obtained and our IC50 values differed from these published Kd values
by 2.4-fold to 6-fold (Table 1). Using our ATPase assay, the average Hill slopes for this
panel of inhibitors ranged from 0.93 to 1.1 (see Table 1) which was indicative of a single
enzyme species being measured. Furthermore, at high concentrations, all compounds were
able to completely inhibit the enzyme activity (Fig. 2C). The compounds in this set were
tested for assay interference by adding compound after completion of the MEKK2 enzyme
reaction. None of these compounds demonstrated inhibition of the assay format (data not
shown). Thus, this panel of structurally diverse and varied potency inhibitors confirmed
enzymatic purity of the ATPase activity assay, i.e. a single enzyme species was generating
signal. In addition, the comparable IC50 data between our MEKK2 ATPase activity assay
and reported MEKK2 binding assays indicated that genuine MEKK2 activity was being
measured.
Validation of a miniaturized semi-automated high throughput MEKK2 activity assay
We converted this MEKK2 activity assay into a less expensive semi-automated high
throughput assay by reducing volume size from 25 to 5 μl and using pin tools to deliver
compound. We assessed assay variability by setting up whole 384-well plates of maximum
and minimum signal wells by including or excluding enzyme, respectively, and using
DMSO instead of compound (Suppl. Fig. S1A). ‘No enzyme’ signal mimics signal at high
concentration of inhibitor in this assay (see Fig. 2C). The Z’-factors calculated from these
duplicate HTS validation experiments were 0.68 and 0.77. We tested the validity of the HTS
version of the assay to reproducibly and accurately determine compound potency values by
performing IC50 determinations with the control inhibitors sunitinib and dasatinib (Fig. 3).
This HTS version of the MEKK2 ATPase assay generated IC50 values and SDs of 963 ± 178
nM and 1,656 ± 319 nM for sunitinib and dasatinib, respectively. These IC50 values are
within 3-fold of the values determined in the manual assay (see Table 1) and acceptable
reproducibility with %CVs of <20%. As a final validation step, the small Prestwick
collection of predominately Food and Drug Administration (FDA)-approved drugs was
screened using the semi-automated HTS version of the MEKK2 ATPase assay (Suppl. Fig.
S1B). The Z’-factors for this screen ranged from 0.61 to 0.78, with an average of 0.71. No
actives (≥50% inhibition) were obtained.
Screening for MEKK2 inhibitors using the intrinsic ATPase activity assay
A kinase-focused library consisting of 4,727 compounds was screened to identify novel
MEKK2 inhibitors (Suppl. Fig. S1C). The Z’-factors for this screen ranged from 0.53 to
0.86, with an average of 0.72. Only 2 actives (≥50% inhibition) were obtained. In order to
identify other control inhibitors of MEKK2 kinase activity, we screened a small collection
of 13 kinase inhibitors, 11 of which are FDA-approved drugs and 2 are in clinical trials.
Sunitinib was employed as an internal control. These compounds were screened at 1 μM
concentration in the MEKK2 intrinsic ATPase assay and 3 hits (≥50% inhibition) were
obtained (Fig. 4A). The hits were pazopanib, crizotinib and bosutinib.
IC50 determinations of hit compounds using three different MEKK2 assay formats:
intrinsic ATPase, binding, and transphosphorylation assays
The active compounds from screening were initially confirmed by IC50 determination using
the intrinsic ATPase activity assay. In regard to the large kinase-focused library screen, only
one of the 2 actives repeated activity in IC50 confirmation using the intrinsic ATPase assay –
this hit compound was referred to as compound 1. Compound 1 generated in IC50 of 299 ±
71 nM in this assay (Fig. 4B and Table 2). A close analog of this compound (compound 2)
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was also tested and found to be inactive (>30 μM IC50) and thus served as a specificity
control (Fig. 4B and Table 2). From the screening of 13 known kinase inhibitors, pazopanib,
crizotinib and bosutinib confirmed activity with IC50 values (± SD) in the ATPase assay of
698 ± 163, 75 ± 35 and 59 ± 34 nM, respectively (Fig. 4C and Table 2).
We employed a TR-FRET MEKK2 binding assay as an orthogonal secondary assay to
further validate the intrinsic ATPase activity assay and to confirm ATPase assay screening
hits. This binding assay measures the binding of compound to the ATP pocket of MEKK2.
The MEKK2 binding assay was optimized as indicated by the reagent manufacturer’s
instructions (Invitrogen Lanthascreen Eu Kinase Binding Assay) using the same source of
MEKK2 enzyme and assay buffer. Concentration response data for sunitinib was generated
using the MEKK2 binding assay (Table 2). The average IC50 value and SD in the binding
assay was 143 ± 6 nM and an average Hill slope of 0.89 ± 0.04. Therefore, the IC50 values
for sunitinib in the ATPase and binding assay differed by only 2.4-fold and our binding data
was very close to the manufacturer’s published IC50 value (120 nM, Table 1). Compound 1
was tested in the MEKK2 binding assay resulting in an average IC50 value of 355 ± 134 nM,
in close agreement with the 299 nM IC50 obtained in the ATPase assay (Table 2). The
inactive control compound 2 was also inactive (>30 μM IC50) in the binding assay. Thus,
compound 1 represents a novel inhibitor of MEKK2. Pazopanib, crizotinib and bosutinib
were also tested in the MEKK2 binding assay resulting in IC50 values (±SD) of 1,145 ± 211,
24 ± 7 and 64 ± 17 nM, respectively (Table 2). The Hill slopes for these compounds in both
binding and ATPase assays, were close to expected for single site binding, ranging from
0.93 – 1.3 (see Table 2). None of the compounds in Figure 4, Table 1 and Table 2
demonstrated any significant assay interference in either the ATPase or binding assay format
(data not shown). Thus, the MEKK2 binding assay data confirmed the MEKK2 inhibitory
activity of these compounds discovered with the MEKK2 intrinsic ATPase assay.
Furthermore, this panel of five diverse inhibitors (Table 2) demonstrated ≤3-fold difference
in IC50 values when comparing the ATPase and binding assay data.
In order to further validate the screening hits and the ATPase assay, we developed a
transphosphorylation assay in which kinase-inactive mutant MKK6 was used as a substrate
in MEKK2 enzyme reactions. Stopped reaction mixtures were transferred to membranes
using a slot blot protocol and phosphorylation of MKK6 was measured by a phospho-MKK6
specific antibody. The average apparent Km for ATP in this assay format was determined to
be 3.3 μM (data not shown) which is 10-fold lower than in the ATPase assay. Therefore, we
used 3 μM ATP in the transphosphorylation assay. Average IC50 values generated using this
transphosphorylation assay for sunitinib, compound 1, crizotinib and bosutinib were 158,
261, 37, 29 nM (Table 2). These values differ by ≤2.2-fold compared to the ATPase and
binding assay potency values. Using a bead-based MEKK2 binding assay as part of a large
kinase profiling panel, it has been reported that pazopanib, crizotinib and bosutinib have Kd
values of 290, 72 and 30 nM, respectively30. Thus, our ATPase data, as well as that from
two other formats, are in close agreement with this published binding data. Furthermore, our
data confirm that these compounds actually inhibit MEKK2 kinase activity. This multiple
format comparison data further enhanced the validation of the intrinsic ATPase assay as a
useful assay for the discovery of MEKK2 inhibitors.
DISCUSSION
We sought to develop a high throughput activity assay for MEKK2. Unlike many kinases,
MEKK2 and many other members of the MAPK family do not effectively use small
synthetic peptides as substrates. Thus, large protein substrates are typically used to measure
MEKK2 activity. However, for HTS this would require large amounts of protein substrate.
In developing a biochemical activity assay for MEKK2, we discovered that purified
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MEKK2 had intrinsic ATPase activity. This ATPase activity was discovered using a
‘universal’ chemiluminescent ADP detection kit. Although convenient, this type of detection
assay requires careful validation to ensure that the observed activity derives from the target
kinase (enzyme identity) and no other kinases or ATPases (enzymatic purity). Trace
amounts of contaminating ATPases or other kinases in the MEKK2 preparation could also
cause the observed ATPase activity.
Multiple independent methods and data were used to verify that the observed ATPase
activity derived from MEKK2. First, the identity of the commercially obtained enzyme
solution was confirmed to be human MEKK2 by MS and no other proteins were identified
in the solution. Second, we compared three different sources of recombinant baculovirus-
expressed and purified MEKK2. All three demonstrated ATPase activity in the absence of
added substrate and even the specific activity was similar amongst the MEKK2 sources.
Unlike the other two vendors’ constructs which were full length proteins, one of the
vendor’s MEKK2 consisted of only the kinase domain of MEKK2, yet still maintained
ATPase activity. Furthermore, IC50 value determination for the control kinase inhibitor
sunitinib using all three sources of MEKK2 resulted in IC50 values within two-fold of each
other, suggestive of measuring the same activity. Third, inhibitor-based studies were
performed using a panel of 4 inhibitors that had been tested in the MEKK2 binding assay
reported by Invitrogen. IC50 values measured using the ATPase assay were comparable
(within 2- to 4-fold) to Invitrogen’s MEKK2 binding assay data. In addition, our data was
also consistent with published potencies using a bead-based competition binding assay used
for kinome profiling30. Dasatinib was reported to have a binding Kd value that is 5.4-fold
lower than the IC50 we observed in the ATPase assay (Table 1). The reason for this
discrepancy may be due, in part, to the expected lower values for Kd versus IC50 values. In
addition, binding assays may give different potencies compared to activity assays possibly
due to different affinities for different activation states of the MEKK2 enzyme preparations
used in the respective studies. This may be a compound-specific effect that is observed with
some inhibitors, but not all. Fourth, format comparison studies were performed with 6
compounds for which we determined IC50 values using the luminescent ATPase and TR-
FRET binding assays. This panel of five diverse inhibitors demonstrated ≤ 3-fold difference
in IC50 values when comparing the ATPase and binding assay data. Thus, there was a
striking correlation between inhibition of the ATPase assay and the MEKK2 binding assay,
even though these assays measured two different parameters – enzyme activity and ATP
pocket binding. In addition, a transphosphorylation assay was developed for MEKK2 using
MKK6 as a substrate. The IC50 values for 4 of these inhibitors were tested in this activity
format as well and all the values were within 2-fold of the ATPase assay values. Taken
together, these data indicate that the ATPase activity measured in our assay is derived from
MEKK2.
In this type of non-selective kinase assay format, it is always possible that multiple enzymes
contribute to assay signal – such as the intended target and trace impurities with high
specific activity. The inhibition of two or more enzymes by an inhibitor generally results in
a blended IC50 curve, due to different binding affinities, resulting in a shallow slope (< 1).
The Hill slopes across all 8 diverse inhibitors tested in this study were close to the ideal (1.0)
for a single enzyme species, ranging from 0.93 to 1.3. A panel of inhibitors such as this
provides strong evidence for enzymatic purity since even similar kinases would be expected
to have slightly different affinities for some of the inhibitors. It is also possible that potential
contaminating ATPase activity is not inhibited by the inhibitors, yet contributes to assay
signal. However, this is not the case since all compounds demonstrated complete inhibition
of activity at high compound concentrations, consistent with only one homogenous enzyme
activity detected.
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A screen of a kinase-focused set of compounds with the MEKK2 ATPase assay resulted in
one confirmed hit (IC50 = 299 nM), representing a hit rate of 0.02%. Further screening of a
set of known FDA-approved and clinical trial kinase inhibitors generated a hit rate of 23%
(3 hits out of 13 compounds). The dramatically different hit rates in these screens is likely
due to the types of compounds in the respective libraries – one being un-optimized
theoretical inhibitors and the other consisting of potent “optimized” kinase inhibitor
scaffolds. Bosutinib and crizotinib were identified as potent (<100 nM IC50) in vitro
inhibitors of MEKK2 kinase activity, confirming and extending a published report on the
binding activity of these compounds for MEKK2. In addition, a novel inhibitor (compound
1) was identified through screening using the ATPase assay and its activity confirmed in the
MEKK2 binding and transphosphorylation formats.
The described MEKK2 ATPase assay has several advantages as a HTS assay. This assay
does not require large amounts of expensive and difficult to produce protein substrate and it
can be miniaturized. Unlike the binding assay, this assay has the potential to identify non-
ATP competitive inhibitors. It should be noted that the Km for ATP differed by 10-fold
between the ATPase and the transphosphorylation assay (30 vs. 3 μM), highlighting the
importance of experimentally determining Km for ATP when developing an ATPase kinase
assay. This magnitude of shift in ATP Km for kinase intrinsic ATPase activity has been
previously observed25.
We have developed and optimized a high throughput activity assay for MEKK2 based on
the discovery that MEKK2 has intrinsic ATPase activity. This activity assay for MEKK2
was validated for enzyme identity and enzymatic purity by multiple methods to demonstrate
that genuine MEKK2 activity was being measured and no other contaminating activities
contribute to the signal. Furthermore, a miniaturized version of the assay was validated for
HTS and compound libraries screened. MEKK2 inhibitors were identified that may be
useful as research tools or lead to potent and selective MEKK2 inhibitors.
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DMSO dimethyl sulfoxide
RLU relative luminescence units
RFU relative fluorescence units
MAPK mitogen-activated protein kinase
MS mass spectrometry
ATP adenosine triphosphate
ADP adenosine diphosphate
GST glutathione S-transferase
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SD standard deviation
TR-FRET time-resolved fluorescence resonance energy transfer
HTS high throughput screening
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Fig. 1. MEKK2 intrinsic ATPase activity assay characterization
(A) Assay signal in response to MEKK2 enzyme concentration was assessed. (B) Assay
signal linearity with respect to reaction times, as indicated, was determined. (C) The Km for
ATP was determined using different concentrations of ATP as indicated, with and without
MEKK2. Signal obtained without MEKK2 was taken as assay background for each ATP
concentration tested. This value was subtracted from the respective assay signal with
MEKK2 to obtain specific RLU values. (D) The assay signal at the indicated concentrations
of DMSO was determined. Data points represent the average of three determinations per
variable and error bars represent standard deviation. Data are representative of three
independent experiments.
Ahmad et al. Page 13
J Biomol Screen. Author manuscript; available in PMC 2014 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2. Intrinsic ATPase activity observed from different sources of purified MEKK2 and used to
determine IC50 values for a panel of kinase inhibitors
(A) Intrinsic ATPase assay reaction time courses were performed using three different
sources of purified MEKK2 obtained from three different vendors: vendor 1(■), vendor 2
(●), and vendor 3 (▲). (B) Concentration response data for sunitinib was normalized to
controls with and without enzyme and plotted as percent activity. These IC50 value
determinations resulted in average IC50 values of 337, 184, and 315 nM using MEKK2 from
vendor 1, 2, and 3, respectively, and average Hill slopes of 1.0 – 1.1 as indicated. (C)
Concentration response data for a panel of kinase inhibitors was normalized to controls with
and without MEKK2 and plotted as percent activity. Potency determinations for sunitinib
(■), dasatinib (●), VX-680 (▼), and staurosporine (◆) resulted in average IC50 values
(nM) and SDs of 337 ± 157, 753 ± 268, 3,603 ± 826, 1.0 ± 0.6, respectively. The average
Hill slope values derived from the IC50 curves for these compounds ranged from 0.93 –
1.10. Data points represent the average of three determinations per concentration and error
bars represent standard deviation. Data are representative of three independent experiments.
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Figure 3. Validation of the high throughput MEKK2 activity assay
The intrinsic ATPase activity assay was performed using a low volume 384-well plate
format with a total enzyme reaction volume of 5 μl. IC50 variability experiments were
performed with the semi-automated high throughput screening activity assay using two
control inhibitors. IC50 determinations for sunitinib (■) and dasatinib (●) resulted in
average IC50 values (nM) ± SD of 963 ± 178 and 1,656 ± 319, respectively. Data are
representative of three independent experiments.
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Figure 4. MEKK2 inhibitory activity of a panel of known kinase inhibitors and IC50
determination for screening hits
(A) A panel of marketed and clinical trial kinase inhibitors was screened at 1 μM compound
concentration using the MEKK2 activity assay. The compounds were screened in duplicate
wells in three independent experiments and the normalized data from all experiments was
aggregated by averaging percent inhibition values obtained from all experiments and
plotting them as shown. Error bars represent standard deviation of the three experiments. (B)
Concentration response data for the hit compound from the large kinase-focused library
screen and a structural analog was normalized to controls with and without MEKK2 and
plotted as percent specific activity. One hit (compound 1, ●) confirmed activity with an
average IC50 of 299 ± 71 nM and a close structural analog (compound 2, ■) resulted in an
IC50 of >30 μM. IC50 data are representative of at least three independent experiments. (C)
The compounds resulting in ≥50% inhibition from the known kinase inhibitor panel were
tested in concentration response experiments, except for sunitinib which was used as a
control. IC50 determinations for bosutinib (■), crizotinib (●), and pazopanib (▲) resulted in
IC50 values (nM) and SD of 59 ± 34, 75 ± 35, 698 ± 163, respectively. IC50 data are
representative of three independent experiments.
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Table 1
MEKK2 Intrinsic ATPase Assay Control Inhibitor Potency Data Compared to Literature Values
Compound
MEKK2 Intrinsic ATPase Assaya Published MEKK2 Binding Assayb Published MEKK2 Binding Assayc
IC50 ± SD (nM) Hill Slope ± SD IC50 (nM) Kd (nM)
Sunitinib 337 ± 157 1.06 ± 0.16 120 57
Dasatinib 753 ± 268 1.10 ± 0.20 960 140
Staurosporine 1.0 ± 0.6d 0.93 ± 0.13 4.2 2.4
VX-680 3,603 ± 826 0.97 ± 0.13 2,300 1,100
a
IC50 value determinations were performed at least three times with average IC50 values and Hill slopes provided with standard deviations (SD).
b
TR-FRET Binding Assay: Invitrogen Lanthascreen™ Eu Kinase Binding Assay for MEKK2 Validation Packet (http://tools.invitrogen.com/
content/sfs/manuals/MAP3K2_LanthaScreen_Binding.pdf)
c
Bead-based competition binding assay30.
d
Staurosporine IC50 determinations were performed using 1 nM (instead of 10 nM) MEKK2 enzyme in the activity assay.
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